159 related articles for article (PubMed ID: 33790481)
1. Retrospective Analysis of Clinical Outcomes Associated With the Use of Pegfilgrastim On-body Injector in Patients Receiving Chemotherapy Requiring Granulocyte Colony-Stimulating Factor Support.
Patel J; Rainess RA; Benfield MJ; Rogers KML; Moore DC; Larck C; Arnall JR
Hosp Pharm; 2021 Apr; 56(2):77-80. PubMed ID: 33790481
[No Abstract] [Full Text] [Related]
2. Two decades of pegfilgrastim: what have we learned? Where do we go from here?
De Oliveira Brandao C; Lewis S; Sandschafer D; Crawford J
Curr Med Res Opin; 2023 May; 39(5):707-718. PubMed ID: 36976784
[TBL] [Abstract][Full Text] [Related]
3. A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices.
Rifkin RM; Crawford J; Mahtani RL; Dale DC; Narang M; MacLaughlin WW; Huynh C; Gawade PL; Lewis S; DeCosta L; Lawrence T; Belani R
Support Care Cancer; 2022 Oct; 30(10):7913-7922. PubMed ID: 35732748
[TBL] [Abstract][Full Text] [Related]
4. A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.
Mahtani RL; Belani R; Crawford J; Dale D; DeCosta L; Gawade PL; Huynh C; Lawrence T; Lewis S; MacLaughlin WW; Narang M; Rifkin R
Support Care Cancer; 2022 Jul; 30(7):6135-6144. PubMed ID: 35426046
[TBL] [Abstract][Full Text] [Related]
5. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
[No Abstract] [Full Text] [Related]
6. Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment.
McBride A; MacDonald K; Fuentes-Alburo A; Abraham I
J Med Econ; 2021; 24(1):598-606. PubMed ID: 33866947
[TBL] [Abstract][Full Text] [Related]
7. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy.
Schenfeld J; Gong T; Henry D; Kelsh M; Gawade P; Peng Y; Bradbury BD; Li S
Support Care Cancer; 2022 Jul; 30(7):6327-6338. PubMed ID: 35482126
[TBL] [Abstract][Full Text] [Related]
8. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy.
Gawade PL; Li S; Henry D; Smith N; Belani R; Kelsh MA; Bradbury BD
Support Care Cancer; 2020 Sep; 28(9):4413-4424. PubMed ID: 31919669
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a novel medical device for pegfilgrastim administration.
Aruga T; Doihara H; Yanagita Y; Ishida T; Yamashita T; Uehara K; Taira T; Tsurutani J; Takeshita T; Tsuyuki S; Kaneko K; Ohtake T; Yamaguchi Y; Hara Y; Saji S
Cancer Sci; 2022 May; 113(5):1763-1770. PubMed ID: 35293085
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants.
Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
Adv Ther; 2024 Mar; 41(3):991-1009. PubMed ID: 38180721
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
[TBL] [Abstract][Full Text] [Related]
12. Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.
Mądry R; Popławska L; Haslbauer F; Šafanda M; Ghizdavescu D; Benkovicova J; Csőszi T; Mihaylov G; Niepel D; Jaeger C; Frkanova I; Macovei A; Staudigl C
Wien Klin Wochenschr; 2016 Apr; 128(7-8):238-47. PubMed ID: 26745973
[TBL] [Abstract][Full Text] [Related]
13. Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey.
Brett Hauber A; Mange B; Price MA; Wolin D; Bensink M; Kaye JA; Chandler D
Support Care Cancer; 2018 Jan; 26(1):251-260. PubMed ID: 28785862
[TBL] [Abstract][Full Text] [Related]
14. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
[TBL] [Abstract][Full Text] [Related]
15. On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status.
Abraham I; Crawford J; Schwartzberg L
Cancer Treat Res Commun; 2024 May; 40():100824. PubMed ID: 38865836
[TBL] [Abstract][Full Text] [Related]
16. Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients.
Metz M; Semsek D; Rogmans G; Hutzschenreuter U; Fietz T; Harde J; Zacharias S; Hielscher C; Lorenz A; Zahn MO; Guth D; Liebers S; Berghorn M; Grebhardt S; Matillon CD; Egerer G; Potthoff K
Support Care Cancer; 2021 Nov; 29(11):6633-6643. PubMed ID: 33956213
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
Lyman G; Lalla A; Barron R; Dubois RW
Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
[TBL] [Abstract][Full Text] [Related]
18. Health professionals' preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia.
Larrarte-González MA; Pineda-Posada M; Gaitán ÁA; Amaya-Amaya J; Ojeda K
BMC Health Serv Res; 2023 May; 23(1):529. PubMed ID: 37221537
[TBL] [Abstract][Full Text] [Related]
19. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
20. Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment.
Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
Curr Med Res Opin; 2019 Jun; 35(6):1073-1080. PubMed ID: 30550346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
